Biomarker testing looks for features of a cancer that may help guide treatment. A test might examine genes, proteins, or other characteristics. You may hear it called molecular profiling, tumor testing, or genomic testing. The names can overlap, so ask what the particular laboratory test actually measures.
A test result is useful when it helps answer a specific clinical question. Ordering the widest possible panel is not automatically the best choice for every cancer or every point in treatment.
Tumor testing and inherited testing answer different questions
Tumor biomarker testing examines the cancer's features. Testing for inherited cancer risk asks whether a person was born with a genetic change that may matter to them and their relatives. These are different purposes, even when similar gene names appear on both reports.
A tumor result can sometimes raise a question about inherited risk. It does not by itself establish that relatives carry the same change. Ask whether separate genetic counseling or testing is appropriate. NCI explains the distinction and uses of biomarker testing.
What testing may help with
A result may identify a treatment directed at a particular cancer feature or help determine eligibility for a clinical trial. Sometimes testing identifies an option to avoid because a tumor is unlikely to respond. Its value depends on the cancer type, the treatment setting, and the evidence supporting the result.
Finding a matching feature does not guarantee that a treatment will work. A result may also show no actionable finding, inadequate material, or a variant of uncertain significance. An uncertain finding should not be treated as a proven reason to change therapy.
Clarify the sample and the timing
Testing may use preserved tissue from an earlier biopsy, a new tissue sample, or blood. A blood-based “liquid biopsy” can be helpful in some situations, but it is not interchangeable with tissue testing for every purpose. A negative blood result may leave questions unanswered.
Ask whether the existing sample has enough material and whether sending it for one test affects availability for another. NCI's cancer diagnosis overview describes how biopsy and other testing contribute to diagnosis.
Make a practical plan for the waiting period. Write down the expected turnaround, who receives the report, and whether another treatment decision can proceed before results arrive. Do not assume that waiting is either harmless or dangerous; ask the treating team about your situation.
Read the result as a decision document
For the results visit, request a copy of the complete report. Create three headings in your notes: finding, evidence, and next step. Ask the clinician to place each relevant result under those headings.
An illustrative question is: “This report lists a gene change. Is there an established treatment for my cancer and treatment setting, or is this mainly a research finding?” That question separates a laboratory observation from a practical care option.
If a trial is discussed, request its identifier and the study team's contact information. An entry in a laboratory report does not establish that a trial is open, nearby, or suitable.
A short pre-test checklist
- What decision is the test meant to support?
- Which sample will be used, and could another biopsy be needed?
- What are the likely costs and coverage questions?
- What happens if the result is negative or inconclusive?
- Who will explain the report and document the treatment decision?
- Could the results raise inherited-risk questions?
Keep results available for future consultations, but ask whether new testing might be useful if the cancer changes or returns. A report is a snapshot of the tested sample, not a permanent guarantee about every cancer cell.
